Advertisement

Advertisement

ELCC 2018 European Lung Cancer Congress

Advertisement

Advertisement

Jun

01

Today In Oncology

Early Local Therapy Did Not Extend Survival in Patients With Newly Diagnosed Metastatic Breast Cancer

Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML

Durvalumab Added to Standard Chemotherapy Improved OS in Patients With Malignant Pleural Mesothelioma

Carfilzomib vs Bortezomib in Addition to Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma

First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer

Advertisement

Most Read Stories

Is Estrogen Protective Against COVID-19?

ESMO Breast 2020: Novel Biomarkers May Predict Immunotherapy Benefit in Metastatic Breast Cancer

Maintenance Avelumab Improves Survival in Advanced Bladder Cancer

FDA Approves Nivolumab/Ipilimumab Plus Chemotherapy for First-Line Treatment of Metastatic or Recurrent NSCLC

Ivosidenib for IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma

Most Viewed Videos

David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?

Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease

Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Urothelial Cancer: The JAVELIN Bladder 100 Study on Avelumab vs Best Supportive Care

Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone

Nancy U. Lin, MD, on Metastatic Breast Cancer: Tucatinib, Trastuzumab, and Capecitabine

© 2020 HSP News Service, L.L.C.